Vaporox

The Next Generation of Advanced Wound Care

News

MIMEDX Announces Strategic Collaboration with Vaporox, Inc.

Relationship Establishes Co-Promotion and Co-Marketing of MIMEDX’s Leading Placental Allograft Portfolio and Vaporox’s Vaporous Hyperoxia Treatment Device

MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the agreement, MIMEDX has made an investment in Vaporox and the Company has certain exclusivity rights related to potential acquisition discussions.

Retrospective Analysis of the Effect of Vaporous Hyperoxia Therapy as an Adjunct to Standard Wound Care in Chronic Wounds

A newly published retrospective study of 53 chronic wounds reinforces the effectiveness of Vaporox’s VHT technology in accelerating the healing of chronic wounds, including diabetic foot ulcers (DFUs), venous leg ulcers, and pressure injuries.

By combining ultrasonic mist and concentrated oxygen therapy, VHT optimizes wound bed preparation and promotes healing, even in complex cases with multiple comorbidities. These findings highlight VHT as a safe and effective adjunct therapy for chronic wounds.

Vaporox Announces FDA Clearance for Its Next Generation Wound Care Medical Device

Vaporox, a Denver based medical device company, has received clearance from the US Food and Drug Administration for its next generation VHT-200 medical device system for healing chronic wounds, which are wounds that do not respond to conventional wound treatment, meeting a significant unmet medical need for millions of sufferers of diabetic foot ulcers.

Colorado BioScience Association’s Post on LinkedIn

In our new BioScience Colorado Magazine, CBSA highlights how companies have raised critical capital. Colorado’s angel community, including Rockies Venture Club, played an integral role in Vaporox Inc.‘s fundraising efforts. After taking the CEO role and forging a commercialization strategy that capitalized on the company’s remarkable clinical results, Alan Sage found major success in the angel market.